Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares saw strong trading volume on Wednesday following a stronger than expected earnings report. 2,596,624 shares changed hands during trading, an increase of 726% from the previous session’s volume of 314,302 shares.The stock last traded at $4.17 and had previously closed at $3.09.
The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 232.61% and a negative net margin of 642.70%. The company had revenue of $2.05 million for the quarter, compared to analyst estimates of $1.86 million.
A number of research firms recently commented on PRTK. Wedbush restated an “outperform” rating and set a $12.00 price target (down from $17.00) on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. HC Wainwright restated a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, June 26th. LADENBURG THALM/SH SH reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, May 9th. Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 26th. Finally, ValuEngine raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. Paratek Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $19.33.
The firm has a market capitalization of $122.55 million, a price-to-earnings ratio of -1.17 and a beta of 1.81. The company has a current ratio of 14.06, a quick ratio of 13.95 and a debt-to-equity ratio of 14.48. The business has a 50 day simple moving average of $3.58.
Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Read More: What is a good dividend yield?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.